Literature DB >> 18223320

New markers of pancreatic cancer identified through differential gene expression analyses: claudin 18 and annexin A8.

Zarir E Karanjawala1, Peter B Illei, Raheela Ashfaq, Jeffrey R Infante, Kathleen Murphy, Akhilesh Pandey, Richard Schulick, Jordan Winter, Rajni Sharma, Anirban Maitra, Michael Goggins, Ralph H Hruban.   

Abstract

BACKGROUND: New markers to distinguish benign reactive glands from infiltrating ductal adenocarcinoma of the pancreas are needed.
DESIGN: The gene expression patterns of 24 surgically resected primary infiltrating ductal adenocarcinomas of the pancreas were compared with 18 non-neoplastic samples using the Affymetrix U133 Plus 2.0 Arrays and the Gene Logic GeneExpress Software System. Gene fragments from 4 genes (annexin A8, claudin 18, CXCL5, and S100 A2) were selected from the fragments found to be highly expressed in infiltrating adenocarcinomas when compared with normal tissues. The protein expression of these genes was examined using immunohistochemical labeling of tissue microarrays.
RESULTS: Claudin 18 labeled infiltrating carcinomas in a membranous pattern. When compared with normal and reactive ducts, claudin 18 was overexpressed, at least focally, in 159 of 166 evaluable carcinomas (96%). Strong and diffuse claudin 18 overexpression was most often seen in well-differentiated carcinomas (P=0.02). Claudin 18 was overexpressed in 51 of 52 cases (98%) of pancreatic intraepithelial neoplasia. Annexin A8 was at least focally overexpressed in 149 of 154 evaluable infiltrating carcinomas (97%). S100 A2 was at least focally overexpressed in 118 of 154 evaluable infiltrating carcinomas (77%). Non-neoplastic glands also frequently expressed S100 A2 diminishing its potential diagnostic utility. Immunolabeling with antibodies directed against CXCL5 did not reveal any significant differences in protein expression between infiltrating adenocarcinomas and normal pancreatic ducts.
CONCLUSIONS: Claudin 18 and annexin A8 are frequently highly overexpressed in infiltrating ductal adenocarcinomas when compared with normal reactive ducts, suggesting a role for these molecules in pancreatic ductal adenocarcinomas. Furthermore, these may serve as diagnostic markers, as screening tests and as therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18223320      PMCID: PMC2678811          DOI: 10.1097/PAS.0b013e31815701f3

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  58 in total

1.  Gene expression profiles of microdissected pancreatic ductal adenocarcinoma.

Authors:  Robert Grützmann; Melanie Foerder; Ingo Alldinger; Eike Staub; Thomas Brümmendorf; Stefan Röpcke; Xinzhong Li; Glen Kristiansen; Ralf Jesenofsky; Ralf Jesnowski; Bence Sipos; Matthias Löhr; Jutta Lüttges; Detlef Ockert; Günter Klöppel; Hans Detlev Saeger; Christian Pilarsky
Journal:  Virchows Arch       Date:  2003-08-27       Impact factor: 4.064

2.  Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast.

Authors:  Scott L Kominsky; Pedram Argani; Dorian Korz; Ella Evron; Venu Raman; Elizabeth Garrett; Alan Rein; Guido Sauter; Olli-P Kallioniemi; Saraswati Sukumar
Journal:  Oncogene       Date:  2003-04-03       Impact factor: 9.867

3.  Diagnosing pancreatic cancer using methylation specific PCR analysis of pancreatic juice.

Authors:  Noriyoshi Fukushima; Kimberly M Walter; Takashi Uek; Norihiro Sato; Hiroyuki Matsubayashi; John L Cameron; Ralph H Hruban; Marcia Canto; Charles J Yeo; Michael Goggins
Journal:  Cancer Biol Ther       Date:  2003 Jan-Feb       Impact factor: 4.742

4.  Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray.

Authors:  Haiyong Han; David J Bearss; L Walden Browne; Robert Calaluce; Raymond B Nagle; Daniel D Von Hoff
Journal:  Cancer Res       Date:  2002-05-15       Impact factor: 12.701

5.  Claudin-4 expression decreases invasiveness and metastatic potential of pancreatic cancer.

Authors:  Patrick Michl; Claudia Barth; Malte Buchholz; Markus M Lerch; Monika Rolke; Karl-Heinz Holzmann; Andre Menke; Heiko Fensterer; Klaudia Giehl; Matthias Löhr; Gerhard Leder; Takeshi Iwamura; Guido Adler; Thomas M Gress
Journal:  Cancer Res       Date:  2003-10-01       Impact factor: 12.701

6.  Novel markers of pancreatic adenocarcinoma in fine-needle aspiration: mesothelin and prostate stem cell antigen labeling increases accuracy in cytologically borderline cases.

Authors:  Denis M McCarthy; Anirban Maitra; Pedram Argani; Anne E Rader; Douglas O Faigel; N Tjarda Van Heek; Ralph H Hruban; Robb E Wilentz
Journal:  Appl Immunohistochem Mol Morphol       Date:  2003-09

7.  Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer.

Authors:  Craig D Logsdon; Diane M Simeone; Charles Binkley; Thiruvengadam Arumugam; Joel K Greenson; Thomas J Giordano; David E Misek; Rork Kuick; Samir Hanash
Journal:  Cancer Res       Date:  2003-05-15       Impact factor: 12.701

8.  Expression profiling of microdissected pancreatic adenocarcinomas.

Authors:  Tatjana Crnogorac-Jurcevic; Evangelos Efthimiou; Torsten Nielsen; Julie Loader; Benoit Terris; Gordon Stamp; Antonella Baron; Aldo Scarpa; Nicholas R Lemoine
Journal:  Oncogene       Date:  2002-07-04       Impact factor: 9.867

9.  Molecular alterations in pancreatic carcinoma: expression profiling shows that dysregulated expression of S100 genes is highly prevalent.

Authors:  Tatjana Crnogorac-Jurcevic; Edoardo Missiaglia; Ekaterina Blaveri; Rathi Gangeswaran; Melanie Jones; Benoit Terris; Eithne Costello; John P Neoptolemos; Nicholas R Lemoine
Journal:  J Pathol       Date:  2003-09       Impact factor: 7.996

10.  Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays.

Authors:  Christine A Iacobuzio-Donahue; Anirban Maitra; Mari Olsen; Anson W Lowe; N Tjarda van Heek; Christophe Rosty; Kim Walter; Norihiro Sato; Antony Parker; Raheela Ashfaq; Elizabeth Jaffee; Byungwoo Ryu; Jessa Jones; James R Eshleman; Charles J Yeo; John L Cameron; Scott E Kern; Ralph H Hruban; Patrick O Brown; Michael Goggins
Journal:  Am J Pathol       Date:  2003-04       Impact factor: 4.307

View more
  46 in total

1.  Claudins 10 and 18 are predominantly expressed in lung adenocarcinomas and in tumors of nonsmokers.

Authors:  Heta Merikallio; Paavo Pääkkö; Terttu Harju; Ylermi Soini
Journal:  Int J Clin Exp Pathol       Date:  2011-09-27

Review 2.  Tight junctions in lung cancer and lung metastasis: a review.

Authors:  Ylermi Soini
Journal:  Int J Clin Exp Pathol       Date:  2012-02-12

3.  Claudin-18 is an early-stage marker of pancreatic carcinogenesis.

Authors:  Mariko Tanaka; Junji Shibahara; Noriyoshi Fukushima; Aya Shinozaki; Makoto Umeda; Shumpei Ishikawa; Norihiro Kokudo; Masashi Fukayama
Journal:  J Histochem Cytochem       Date:  2011-08-10       Impact factor: 2.479

Review 4.  Targeting tight junctions during epithelial to mesenchymal transition in human pancreatic cancer.

Authors:  Daisuke Kyuno; Hiroshi Yamaguchi; Tatsuya Ito; Tsuyoshi Kono; Yasutoshi Kimura; Masafumi Imamura; Takumi Konno; Koichi Hirata; Norimasa Sawada; Takashi Kojima
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

5.  Dynamic distribution of claudin proteins in pancreatic epithelia undergoing morphogenesis or neoplastic transformation.

Authors:  Joby J Westmoreland; Yiannis Drosos; Jacqueline Kelly; Jianming Ye; Anna L Means; M Kay Washington; Beatriz Sosa-Pineda
Journal:  Dev Dyn       Date:  2012-01-31       Impact factor: 3.780

6.  Plectin-1 as a novel biomarker for pancreatic cancer.

Authors:  Dirk Bausch; Stephanie Thomas; Mari Mino-Kenudson; Castillo Carlos Fernández-del; Todd W Bauer; Mark Williams; Andrew L Warshaw; Sarah P Thayer; Kimberly A Kelly
Journal:  Clin Cancer Res       Date:  2010-11-23       Impact factor: 12.531

7.  Truncation of histone H2A's C-terminal tail, as is typical for Ni(II)-assisted specific peptide bond hydrolysis, has gene expression altering effects.

Authors:  Aldona A Karaczyn; Robert Y S Cheng; Gregory S Buzard; James Hartley; Dominic Esposito; Kazimierz S Kasprzak
Journal:  Ann Clin Lab Sci       Date:  2009       Impact factor: 1.256

Review 8.  Roles of the first-generation claudin binder, Clostridium perfringens enterotoxin, in the diagnosis and claudin-targeted treatment of epithelium-derived cancers.

Authors:  Yosuke Hashimoto; Kiyohito Yagi; Masuo Kondoh
Journal:  Pflugers Arch       Date:  2016-09-15       Impact factor: 3.657

Review 9.  A compendium of potential biomarkers of pancreatic cancer.

Authors:  H C Harsha; Kumaran Kandasamy; Prathibha Ranganathan; Sandhya Rani; Subhashri Ramabadran; Sashikanth Gollapudi; Lavanya Balakrishnan; Sutopa B Dwivedi; Deepthi Telikicherla; Lakshmi Dhevi N Selvan; Renu Goel; Suresh Mathivanan; Arivusudar Marimuthu; Manoj Kashyap; Robert F Vizza; Robert J Mayer; James A Decaprio; Sudhir Srivastava; Samir M Hanash; Ralph H Hruban; Akhilesh Pandey
Journal:  PLoS Med       Date:  2009-04-07       Impact factor: 11.069

10.  Involvement of potential pathways in malignant transformation from oral leukoplakia to oral squamous cell carcinoma revealed by proteomic analysis.

Authors:  Zhi Wang; Xiaodong Feng; Xinyu Liu; Lu Jiang; Xin Zeng; Ning Ji; Jing Li; Longjiang Li; Qianming Chen
Journal:  BMC Genomics       Date:  2009-08-19       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.